Get started
SHANDONGJINCHENG PSHANDONGJINCHENG PSHANDONGJINCHENG P

SHANDONGJINCHENG P

18.10CNYD
+0.82+4.75%
At close at 08:49 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

300233 fundamentals

Key facts

Market capitalization‪6.52 B‬CNY
Dividend yield (indicated)0.00%
Price to earnings Ratio (TTM)34.18
Basic EPS (TTM)0.51CNY
Founded2004
Employees (FY)‪3.81 K‬
CEO—
Websitejinchengpharm.com
About

Shandong Jincheng Pharmaceutical Group Co., Ltd. engages in the research and development, bio-pharmaceuticals, production and sale of III and IV cephalosporin intermediates. Its products are categorized into the following divisions: Characteristic Bulk Drugs, Pharmaceutical Intermediates, and Fine Chemicals. The company was founded by Hong Fu Zhao on January 12, 2004 and is headquartered in Zibo, China.

Ownership
‪‪379.33 M‬‬
Free Float shares
‪‪296.86 M‬‬ (78.26%)
Closely held shares
‪‪82.47 M‬‬ (21.74%)
Free Float shares
‪‪296.86 M‬‬ (78.26%)
Closely held shares
‪‪82.47 M‬‬ (21.74%)
Capital structure
Market cap
‪‪6.52 B‬‬
Debt
‪‪748.23 M‬‬
Minority interest
‪‪62.31 M‬‬
Cash & equivalents
‪‪941.29 M‬‬
Enterprise value
‪‪6.39 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪6.52 B‬‬
Price to earning ratio (P/E)
34.18x
Price to sales ratio (P/S)
1.90x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
34.18x
Price to sales ratio (P/S)
1.90x
Valuation ratios
‪0.00‬
‪0.50‬
‪1.00‬
‪1.50‬
‪2.00‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪10.00‬
‪20.00‬
‪30.00‬
‪40.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪2.5%‬
‪4.2%‬
‪5.9%‬
‪7.6%‬
‪9.3%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
‪‪1.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Intermediate
Preparation
Featured Active Pharmaceutical Ingredient
Other
By country
Period: 2023
China
Foreign

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2020
2021
2022
2023
2024
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬
Estimate
Earnings
Next:Mar 28, 2025
2020
2021
2022
2023
2024
‪0.00‬
‪0.50‬
‪1.00‬
‪1.50‬
‪2.00‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
89.00%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
3.13%
Last payment
0.15
Last ex-date
Feb 17, 2025
Dividend history
‪0.65%‬
‪0.95%‬
‪1.25%‬
‪1.55%‬
‪1.85%‬
2018
2019
2020
2021
2023
‪0.00‬
‪0.07‬
‪0.14‬
‪0.21‬
‪0.28‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−400.00 M‬‬
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬
Assets
Liabilities